Autumn 2024

CDMOs & CROs

A draft US Biosecure Act being passed by the US House of Representatives and discussed by the US Senate could prohibit US biotech developers from collaborating with Chinese CROs, CDMOs and drug developers from 2032 by excluding the partners from federal contracts. US companies are unsettled, according to a survey. But how will the impending ban effect innovation, licences and the European sector in short term?

Special topics:

Capacity tripled – Interview with Kai Pohlmeyer, CEO Richter Biologics

Your mRNA Partner in Europe

The key versus larger CMOs is agility and flexibility – Interview with Dr Samanta Cimitan, CEO Celonic Group

Aequorin: superior choice for GPCR calcium signalling

Empowering tomorrow’s therapies today – Interview with Benedikt von Braunmühl, CEO Rentschler Biopharma SE

Pichia protein production

Contact:
Editorial Contact: Thomas Gabrielczyk (t.gabrielczyk@biocom.de)
Marketing Contact: Oliver Schnell (o.schnell@biocom.de), Andreas Macht (a.macht@biocom.de)